SCHEMBL13856646

SCHEMBL13856646

CCn1c(CSc2nc3ccccc3s2)nnc1SCC(=O)c1ccc(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 1.00
KDM4E B2RXH2 7/20 1.00
ALPG P10696 7/20 1.00
LMNA P02545 6/20 1.00
SMN1; SMN2 Q16637 6/20 1.00
GAA P10253 5/20 1.00
HPGD P15428 4/20 1.00
POLB P06746 4/20 1.00
HTT P42858 4/20 1.00
ALPL P05186 3/20 1.00
RECQL P46063 3/20 1.00
APEX1 P27695 3/20 1.00
ALDH1A1 P00352 4/20 0.75
TSHR P16473 3/20 0.75
USP2 O75604 1/20 0.75
GCGR P47871 1/20 0.67
L3MBTL1 Q9Y468 5/20 0.57
ALOX12 P18054 3/20 0.57
TP53 P04637 1/20 0.56
HSD17B10 Q99714 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3466913 0.82 ALPG (1.00) MAPTKDM4EALPGLMNASMN1; SMN2
SCHEMBL26320568 0.75 ALPL (0.80) MAPTKDM4EALPGLMNASMN1; SMN2
SCHEMBL15430002 0.69 POLB (0.62) MAPTKDM4EALPGLMNASMN1; SMN2
Bromide SCHEMBL3871016 0.68 ALPL (0.68) MAPTALPGLMNAGAAHPGD
SCHEMBL4205122 0.68 ALDH1A1 (0.67) MAPTKDM4EALPGLMNASMN1; SMN2
SCHEMBL16210999 0.64 MAPT (0.69) MAPTKDM4EALPGSMN1; SMN2GAA
SCHEMBL15429998 0.64 MEN1 (0.72) MAPTKDM4EALPGLMNASMN1; SMN2
SCHEMBL13461102 0.64 POLB (0.83) MAPTALPGSMN1; SMN2HPGDPOLB
SCHEMBL23196643 0.63 ALPG (0.61) MAPTKDM4EALPGLMNASMN1; SMN2
SCHEMBL13629728 0.63 MAPT (1.00) MAPTALPGSMN1; SMN2HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE (US) 2009-05-07 US disclosed
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE (US) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS BCL2, BAX, BAD MAPT 3866/4885KDM4E 3373/4885ALPG 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.